导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.14% | 2983/4773 |
| 近一周 | -1.77% | 2783/5465 |
| 近一月 | -1.56% | 1192/5421 |
| 近一季 | 0.11% | 984/5231 |
| 近半年 | 0.41% | 1304/4920 |
| 近一年 | -0.79% | 2893/4394 |
| 近两年 | 49.06% | 1526/2954 |
| 近三年 | 34.08% | 941/2253 |
| 成立以来 | 35.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.04% 4012/4961 |
4.42% 2910/5312 |
- - |
- - |
| 2025 | 23.74% 1848/4813 |
-0.12% 2074/3635 |
3.92% 911/4076 |
18.98% 2212/4524 |
0.20% 2137/4813 |
| 2024 | 20.07% 491/3463 |
4.70% 440/2808 |
-2.25% 1162/3014 |
17.16% 1255/3129 |
0.13% 1262/3463 |
| 2023 | -9.65% 1211/2656 |
1.03% 1654/2280 |
-7.04% 1763/2385 |
3.69% 174/2515 |
-7.23% 2096/2655 |
| 2022 | -16.86% 524/2207 |
-12.32% 601/1919 |
7.00% 551/2016 |
-15.11% 1217/2113 |
4.39% 553/2208 |
| 2021 | -7.11% 1029/1822 |
-1.10% 433/1255 |
-1.75% 1176/1330 |
-5.68% 843/1466 |
1.35% 958/1822 |
| 2020 | 21.04% 696/1250 |
-8.51% 616/1028 |
6.28% 867/1067 |
12.58% 376/1164 |
10.57% 590/1184 |
| 2019 | 26.19% 580/1092 |
17.57% 653/754 |
-0.42% 260/804 |
-1.24% 639/850 |
9.14% 254/918 |
| 2018 | -15.64% 102/834 |
- - |
- - |
- - |
-11.28% 277/691 |
| 2017 | 19.18% 197/714 |
- - |
- - |
- - |
- - |
| 2016 | 1.93% 88/605 |
- - |
- - |
- - |
- - |
| 2015 | -1.02% 260/575 |
- - |
- - |
- - |
- - |
| 2014 | 48.76% 93/237 |
- - |
- - |
- - |
- - |
| 2013 | -20.25% 175/186 |
- - |
- - |
- - |
- - |
| 2012 | 16.38% 9/140 |
- - |
- - |
- - |
- - |
| 2011 | -17.47% 15/102 |
- - |
- - |
- - |
- - |
| 2010 | -24.10% 56/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时上证超大盘ETF联接A VS. 长安沪深300非周期A(740101) |